[Treatment of urinary tract infections by cefaclor, with special reference to the antibody-coated bacteria (ACB) detected by the immunoenzyme technique].
Twenty out-patients suffering from urinary tract infections (UTI) were treated with cefaclor. Cefaclor was administrated orally in daily doses of 1,500 mg for 7 days against 15 cases of simple UTI and 5 cases of complicated UTI. Of 20 cases with acute simple cystitis, acute pyelonephritis and complicated UTI, clinical responses were excellent in 10 cases, good in 6 cases and poor in 4 cases. The efficacy rate was 80%. No side effect was observed. The site of infection determined by the ACB detection method was in good agreement with that determined by clinical findings. Cefaclor appeared to be equally effective in the treatment of both ACB-positive and ACB-negative infections. The presence of absence of antibody-coated bacteria did not correlate with clinical symptoms or response to therapy.
D000328:Adult; D000368:Aged; D000919:Antibody-Coated Bacteria Test, Urinary; D002433:Cefaclor / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007124:Immunoenzyme Techniques; D007711:Klebsiella pneumoniae / Q000302:isolation & purification; D008875:Middle Aged; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology
D002433:Cefaclor; D002506:Cephalexin